You are here: Industry Insights > sorafenib

News List

HCC Therapeutic Regimens Rewritten by Tumor Immunotherapies: the 12 Years from Sorafenib to Tumor Immunotherapies PharmaSources/1℃
March 18, 2020
Opdivo kicked off the era of HCC immunotherapies in the world, and AiRuiKa’s taking the lead in receiving the approval for HCC indication in China was an important milestone!
Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma drugs
December 27, 2019
Among patients with metastatic renal cell carcinoma, progression-free survival was longer in those receiving tivozanib versus sorafenib as third- or fourth-line therapy ...
SIRT is better tolerated than sorafenib, but doesn’t increase overall survival in HCC europeanpharmaceuticalreview
May 07, 2019
Results of the SARAH trial demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179)…
FDA Approves Cabozantinib for Hepatocellular Carcinoma americanpharmaceuticalreview
January 17, 2019
On January 14, 2019, the Food and Drug Administration (FDA) approved cabozantinib (CABOMETYX, Exelixis) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib....
MSD’s Keytruda approved for liver cancer pharmatimes
November 14, 2018
US regulators have expanded the use of MSD’s anti-PD-1 therapy Keytruda to include treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.